<DOC>
	<DOC>NCT01073540</DOC>
	<brief_summary>A single dose, two treatments (two cephalexin suspension brands), two sequences, cross-over design was used with a washout of 7 days between the two study periods. Treatment groups balanced with the same number of healthy volunteers who were randomly (in two strata: male and female) assigned to the study drug administration sequences.</brief_summary>
	<brief_title>Cross-over Study to Prove Bioequivalence Between Two Brands of Cefalexin Suspension</brief_title>
	<detailed_description />
	<mesh_term>Cephalexin</mesh_term>
	<criteria>Healthy male or female volunteers age between 18 and 55 years old with normal vital signs, electrocardiogram (ECG), blood chemistry, liver function profile and urinalysis History of illnesses or any organic abnormalities that could affect the results of the study History of tobacco or alcohol abuse or regular use of recreational or therapeutic drugs Subjects that have taken any medication within 14 days or that are in an elimination period of less than 7 halflives (whichever is longest) before study startup</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>